Cronos Group Inc. (CRON)
USD 1.73
(2.68%)
USD 1.73
(2.68%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 96.7 Million USD | -30.95% |
| 2022 | 127.98 Million USD | -28.66% |
| 2021 | 179.38 Million USD | 16.85% |
| 2020 | 153.51 Million USD | 56.18% |
| 2019 | 98.29 Million CAD | 355.73% |
| 2018 | 21.56 Million CAD | 190.44% |
| 2017 | 7.42 Million CAD | 142.0% |
| 2016 | 3.06 Million CAD | 98.06% |
| 2015 | 1.54 Million CAD | -30.35% |
| 2014 | 2.22 Million CAD | 424.82% |
| 2013 | 423.86 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 20.29 Million USD | 27.27% |
| 2024 Q1 | 17.17 Million USD | -14.53% |
| 2023 Q4 | 20.09 Million USD | -21.95% |
| 2023 Q2 | 23.71 Million USD | -2.7% |
| 2023 Q3 | 25.74 Million USD | 8.54% |
| 2023 Q1 | 24.37 Million USD | -16.03% |
| 2023 FY | 88.36 Million USD | -30.95% |
| 2022 Q4 | 29.03 Million USD | -8.24% |
| 2022 Q3 | 31.63 Million USD | 2.33% |
| 2022 Q2 | 30.91 Million USD | -15.06% |
| 2022 FY | 127.98 Million USD | -28.66% |
| 2022 Q1 | 36.39 Million USD | -10.57% |
| 2021 Q3 | 53.75 Million USD | 20.99% |
| 2021 Q4 | 40.69 Million USD | -24.29% |
| 2021 Q1 | 40.49 Million USD | -6.93% |
| 2021 FY | 179.38 Million USD | 16.85% |
| 2021 Q2 | 44.43 Million USD | 9.72% |
| 2020 Q1 | 38.58 Million USD | 1.1% |
| 2020 Q3 | 39.63 Million USD | 24.62% |
| 2020 Q4 | 43.51 Million USD | 9.79% |
| 2020 FY | 153.51 Million USD | 56.18% |
| 2020 Q2 | 31.8 Million USD | -17.58% |
| 2019 Q4 | 38.16 Million CAD | 45.19% |
| 2019 Q3 | 26.28 Million CAD | 31.28% |
| 2019 Q2 | 20.02 Million CAD | 92.69% |
| 2019 Q1 | 10.39 Million CAD | 22.81% |
| 2019 FY | 98.29 Million CAD | 355.73% |
| 2018 Q2 | 4.45 Million CAD | 40.04% |
| 2018 Q1 | 3.17 Million CAD | 42.0% |
| 2018 Q3 | 5.39 Million CAD | 21.18% |
| 2018 FY | 21.56 Million CAD | 190.44% |
| 2018 Q4 | 8.46 Million CAD | 56.83% |
| 2017 Q2 | 2.01 Million CAD | 51.92% |
| 2017 FY | 7.42 Million CAD | 142.0% |
| 2017 Q4 | 2.23 Million CAD | 36.47% |
| 2017 Q3 | 1.64 Million CAD | -18.75% |
| 2017 Q1 | 1.32 Million CAD | -14.2% |
| 2016 Q1 | 335.63 Thousand CAD | -44.09% |
| 2016 Q3 | 789.68 Thousand CAD | 95.07% |
| 2016 Q2 | 404.81 Thousand CAD | 20.61% |
| 2016 Q4 | 1.54 Million CAD | 96.17% |
| 2016 FY | 3.06 Million CAD | 98.06% |
| 2015 Q2 | 337.14 Thousand CAD | -19.05% |
| 2015 Q4 | 600.28 Thousand CAD | 146.03% |
| 2015 FY | 1.54 Million CAD | -30.35% |
| 2015 Q3 | 243.98 Thousand CAD | -27.63% |
| 2015 Q1 | 416.49 Thousand CAD | 0.0% |
| 2014 Q3 | 76.68 Thousand CAD | 697.61% |
| 2014 Q2 | 9613.92 CAD | 0.0% |
| 2014 FY | 2.22 Million CAD | 424.82% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 FY | 423.86 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -1071.822% |
| Alpha Teknova, Inc. | 45.85 Million USD | -110.883% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 50.654% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -115.608% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 39.256% |
| Cosmos Health Inc. | 26.18 Million USD | -269.389% |
| Journey Medical Corporation | 54.59 Million USD | -77.142% |
| Embecta Corp. | 528.4 Million USD | 81.698% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 64.432% |
| Dynavax Technologies Corporation | 219.14 Million USD | 55.87% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 83.609% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 70.369% |
| PainReform Ltd. | 9.58 Million USD | -909.067% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -636.86% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -636.86% |
| SCYNEXIS, Inc. | 51.84 Million USD | -86.524% |
| Safety Shot Inc | 12.1 Million USD | -698.608% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -3050.964% |
| Procaps Group, S.A. | 199.47 Million USD | 51.519% |
| Theratechnologies Inc. | 72.75 Million USD | -32.922% |
| Harrow Health, Inc. | 89.97 Million USD | -7.487% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -923.809% |
| Biofrontera Inc. | 39.95 Million USD | -142.021% |
| DURECT Corporation | 43.71 Million USD | -121.226% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 81.719% |
| OptiNose, Inc. | 85.1 Million USD | -13.639% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 58.337% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -147.003% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 1111.495% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 69.214% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -893.841% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -124.693% |
| Radius Health, Inc. | 265.92 Million USD | 63.634% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -598.668% |
| ProPhase Labs, Inc. | 37.85 Million USD | -155.492% |
| Phibro Animal Health Corporation | 260.29 Million USD | 62.847% |
| Procaps Group S.A. | 187.24 Million USD | 48.352% |
| Alvotech | 285.43 Million USD | 66.119% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -884.316% |
| Viatris Inc. | 5.96 Billion USD | 98.379% |
| Rockwell Medical, Inc. | 15.37 Million USD | -529.043% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -61.613% |
| SIGA Technologies, Inc. | 22.04 Million USD | -338.728% |
| Tilray Brands, Inc. | 251.35 Million USD | 61.525% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -97.212% |
| Shineco, Inc. | 17.94 Million USD | -438.828% |
| PetIQ, Inc. | 192.72 Million USD | 49.82% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -2323.093% |
| Incannex Healthcare Limited | 30.05 Million USD | -221.795% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 93.942% |
| Alimera Sciences, Inc. | 62.64 Million USD | -54.386% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -12583.281% |
| Assertio Holdings, Inc. | 368.58 Million USD | 73.762% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -1543.154% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -443.049% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -356.843% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -359.598% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 41.376% |
| Hempacco Co., Inc. | 7.59 Million USD | -1173.082% |
| Talphera, Inc. | 11.99 Million USD | -706.311% |
| Alvotech | 285.43 Million USD | 66.119% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 31.273% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 71.96% |
| Currenc Group, Inc. | 24 Million USD | -302.919% |
| Kamada Ltd. | 45.42 Million USD | -112.893% |
| Indivior PLC | 911 Million USD | 89.384% |
| Evoke Pharma, Inc. | 12.4 Million USD | -679.305% |
| Flora Growth Corp. | 10.57 Million USD | -814.16% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -359.598% |
| Evolus, Inc. | 189.75 Million USD | 49.036% |
| HUTCHMED (China) Limited | 436.23 Million USD | 77.831% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 37.257% |
| Akanda Corp. | 3.48 Million USD | -2676.196% |